Dimensional Fund Advisors LP Acquires New Holdings in Zura Bio Limited (NASDAQ:ZURA)

Dimensional Fund Advisors LP bought a new stake in shares of Zura Bio Limited (NASDAQ:ZURA) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 37,290 shares of the company’s stock, valued at approximately $93,000. Dimensional Fund Advisors LP owned about 0.06% of Zura Bio at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. American Century Companies Inc. purchased a new position in Zura Bio during the 4th quarter valued at $27,000. Prudential Financial Inc. bought a new position in shares of Zura Bio in the 4th quarter worth approximately $28,000. XTX Topco Ltd bought a new position in shares of Zura Bio in the 4th quarter worth approximately $44,000. SG Americas Securities LLC lifted its stake in shares of Zura Bio by 51.6% in the 4th quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock worth $58,000 after purchasing an additional 7,828 shares during the period. Finally, Wells Fargo & Company MN increased its holdings in Zura Bio by 68.6% in the 4th quarter. Wells Fargo & Company MN now owns 23,053 shares of the company’s stock worth $58,000 after acquiring an additional 9,379 shares in the last quarter. 61.14% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on ZURA shares. Chardan Capital cut their target price on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, March 26th. Oppenheimer decreased their target price on Zura Bio from $19.00 to $17.00 and set an “outperform” rating for the company in a research report on Friday, May 9th. HC Wainwright restated a “buy” rating on shares of Zura Bio in a report on Thursday, April 3rd. Finally, Guggenheim reiterated a “buy” rating and issued a $15.00 target price on shares of Zura Bio in a research note on Wednesday, March 26th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $14.33.

Zura Bio Stock Down 7.5%

Shares of Zura Bio stock opened at $1.11 on Friday. The business’s fifty day simple moving average is $1.28 and its 200-day simple moving average is $1.97. Zura Bio Limited has a 52 week low of $0.97 and a 52 week high of $6.31. The firm has a market cap of $75.90 million, a PE ratio of -1.59 and a beta of 0.05.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). As a group, equities analysts expect that Zura Bio Limited will post -0.65 earnings per share for the current year.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.